R&D News | pharmaphorum

News

Aiolos $245m Series A heads latest crop of biotech rounds

Biotech investment may be somewhat in the doldrums at the moment, but the sector continues to see a steady stream of deals – particularly in the venture capital category –

News

Early result backs Regeneron’s deafness gene therapy

Regeneron’s gene therapy for a profound form of deafness affecting children, DB-OTO, has shown the first signs that it can improve hearing in a clinical trial.

News

Sanofi will exit consumer health and boost R&D investment

Sanofi is following in the footsteps of a number of its peers in pharma with a plan to spin off its consumer health business into a separate company and focus its efforts

News

COVID, flu combo jab from Pfizer/BioNTech heads for phase 3

A combination COVID-19 and influenza vaccine being developed by Pfizer and BioNTech has generated immune responses against the viruses in a phase 1/2 trial, setting up a p

News

First data with subcutaneous Leqembi, and other CTAD news

Eisai and Biogen have reported data showing that a subcutaneous formulation of its Alzheimer’s disease therapy Leqembi matched the current intravenous version at clearing

News

BioXcel shares rise on result of Alzheimer’s drug probe

Shares in BioXcel Therapeutics rose more than 31% in early trading today after the biotech said an independent audit of a phase 3 trial of its Alzheimer’s disease therapy

Aiolos $245m Series A heads latest crop of biotech rounds

Early result backs Regeneron’s deafness gene therapy

Sanofi will exit consumer health and boost R&D investment

COVID, flu combo jab from Pfizer/BioNTech heads for phase 3

First data with subcutaneous Leqembi, and other CTAD news

BioXcel shares rise on result of Alzheimer’s drug probe

Sandoz says it is entering "golden decade" in biosimilars

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks